Pulmonary Surfactant Peptides: Keeping Lungs Open

Lung Peptides

300M alveoli coated by surfactant

Without surfactant proteins SP-B and SP-C, the 70 square meters of lung surface area would collapse with every exhale. These peptides are the reason breathing works.

Braide-Moncoeur et al., Current Opinion in Chemical Biology, 2016

Braide-Moncoeur et al., Current Opinion in Chemical Biology, 2016

View as image

Every time you exhale, your lungs face a physics problem. The 300 million alveoli that exchange oxygen and carbon dioxide are tiny spheres lined with a thin film of water. Surface tension in that water film tries to collapse these spheres shut. If nothing counteracted that force, breathing would require enormous muscular effort, and the smallest alveoli would collapse into the largest ones. The molecules that prevent this are pulmonary surfactant peptides, specifically surfactant proteins B and C (SP-B and SP-C), which work alongside phospholipids to reduce surface tension to near zero during exhalation.^[1] The defensins in your lungs article covers the antimicrobial peptides that protect lung tissue from infection. This article focuses on the structural peptides that keep the lungs physically open.

The Four Surfactant Proteins

Pulmonary surfactant is approximately 90% lipid (mainly dipalmitoylphosphatidylcholine, or DPPC) and 10% protein. Four surfactant proteins have been identified, divided into two functional groups.

Hydrophilic collectins: SP-A and SP-D are large, water-soluble proteins that function primarily in innate immunity. They recognize and bind pathogens, helping the lung clear bacteria and viruses. SP-A is the most abundant surfactant protein by mass, but it contributes relatively little to surface tension reduction.

Hydrophobic peptides: SP-B and SP-C are small, lipid-associated peptides that perform the actual biophysical work of surfactant. SP-B is a homodimer of approximately 8.7 kDa per monomer that organizes phospholipids into the surface-active film. SP-C is even smaller at 3.7 kDa, an extremely hydrophobic peptide with a palmitoylated cysteine residue that anchors it deep within the lipid layer.^[1]

Without SP-B and SP-C, DPPC alone cannot form the highly compressed monolayer needed to reduce surface tension to near zero. The peptides facilitate the rapid adsorption of lipids to the air-water interface during inhalation and maintain film stability during the compression of exhalation.

SP-B: The Critical Surfactant Peptide

SP-B is the most functionally important surfactant protein. It is encoded by the SFTPB gene on chromosome 2 and is produced exclusively by type II alveolar epithelial cells, the same cells that manufacture and secrete surfactant.

SP-B's structure includes multiple amphipathic helices that interact with both the lipid tails and polar headgroups of surfactant phospholipids. This allows SP-B to promote several critical processes: the formation of tubular myelin (a lattice-like storage form of surfactant), the rapid spreading of lipids at the alveolar surface, and the respreading of surfactant after compression.

When SP-B Is Missing

Hereditary SP-B deficiency, caused by loss-of-function mutations in SFTPB, is the most dramatic demonstration of this peptide's importance. The most common mutation, 121ins2 (a two-base insertion in exon 4), accounts for approximately two-thirds of cases. Infants born with homozygous SP-B deficiency present with severe respiratory failure within hours of birth. Unlike premature infants with respiratory distress syndrome (RDS), these full-term babies do not respond to exogenous surfactant therapy because their lungs cannot process or utilize the administered surfactant without functional SP-B.

The condition is uniformly fatal without lung transplantation. Estimated incidence is approximately 1 in 1 million live births. Partial SP-B deficiency, caused by heterozygous mutations or certain polymorphisms, may contribute to susceptibility to RDS in premature infants and to chronic lung disease in adults.

SP-C: The Deeply Buried Peptide

SP-C is the most hydrophobic protein in the human body. Its mature form is only 35 amino acids, with a transmembrane helix that spans the lipid bilayer of surfactant membranes. Two palmitoyl chains covalently attached to cysteines near the N-terminus further anchor SP-C within the lipid environment.

SP-C's primary function is maintaining the stability of the surfactant film during the compression-expansion cycles of breathing. While SP-B handles the initial formation and spreading of the surfactant layer, SP-C prevents the film from collapsing or forming unstable aggregates during rapid compression.

Mutations in the SFTPC gene cause a spectrum of interstitial lung diseases rather than the acute respiratory failure seen with SP-B deficiency. Misfolded SP-C protein accumulates in type II cells, triggering endoplasmic reticulum stress and cell death. These conditions can present in infancy or not until adulthood, producing chronic inflammation and fibrosis. The article on peptide approaches to COPD covers related lung disease research.

Surfactant Replacement Therapy: A Peptide Success Story

Before 1990, respiratory distress syndrome was the leading cause of death in premature infants. Babies born before 32 weeks of gestation produce insufficient surfactant because type II alveolar cells are among the last lung cells to mature during fetal development. Without surfactant, the alveoli collapse (atelectasis), and the infant cannot maintain adequate gas exchange.

The introduction of exogenous surfactant replacement therapy transformed neonatal medicine. Early surfactant preparations were derived from animal lungs, primarily bovine (beractant/Survanta) and porcine (poractant alfa/Curosurf). These contain native SP-B and SP-C along with phospholipids. Clinical trials demonstrated approximately 40% reduction in neonatal mortality from RDS, making surfactant replacement one of the most successful pharmaceutical interventions in pediatric medicine.

Current administration involves instilling surfactant directly into the trachea of intubated premature infants, ideally within the first two hours of life. The standard protocol requires brief intubation, surfactant instillation, and then either continued ventilation or rapid extubation to non-invasive support. Less invasive techniques are changing practice. The INSURE method (Intubate-Surfactant-Extubate) minimizes ventilator time. Even less invasive surfactant administration (LISA), which delivers surfactant through a thin catheter while the infant breathes spontaneously on continuous positive airway pressure (CPAP), avoids intubation entirely. Aerosolized surfactant delivery is also under investigation, though achieving adequate alveolar deposition without intubation remains technically challenging.

Synthetic Surfactant Peptides

The first generation of synthetic surfactants contained no proteins and performed poorly compared to animal-derived preparations. The second generation introduced synthetic peptide analogs of SP-B.

Lucinactant (Surfaxin)

Lucinactant, approved by the FDA in March 2012, contains sinapultide (KL4), a 21-amino acid peptide composed of repeating leucine-lysine units designed to mimic SP-B's interaction with phospholipids. The KL4 peptide reproduces the amphipathic helix structure that allows SP-B to organize lipids at the air-water interface.^[1]

In the SELECT trial, lucinactant demonstrated non-inferiority to beractant for preventing RDS-related death and bronchopulmonary dysplasia at 36 weeks. The STAR trial showed similar efficacy compared to poractant alfa. Lucinactant's advantage over animal-derived surfactants is manufacturing consistency, elimination of animal-sourced material concerns, and potentially lower infection risk.

The KL4 peptide has also found applications beyond surfactant therapy. Qiu and colleagues demonstrated in 2019 that PEGylated KL4 could serve as a pulmonary delivery vehicle for mRNA, exploiting the peptide's natural affinity for lung tissue and its ability to penetrate the surfactant layer.^[2]

CHF5633: Next-Generation Synthetic Surfactant

CHF5633, developed by Chiesi Farmaceutici, is the first synthetic surfactant to contain analogs of both SP-B and SP-C. Previous synthetic surfactants like lucinactant included only an SP-B mimic. CHF5633 addresses this gap with two synthetic peptides: an SP-B analog (a 34-residue peptide fragment) and an SP-C analog (a modified version of the native sequence with improved folding stability).

First-in-human clinical trials in premature infants demonstrated that CHF5633 could stabilize lung function comparably to animal-derived surfactants. The inclusion of both hydrophobic surfactant peptides more closely recapitulates the biophysical behavior of native surfactant, particularly the film stability during rapid compression-expansion cycles that SP-C provides. CHF5633 is currently advancing through Phase 2 trials in Europe, and if successful, would become the first fully synthetic surfactant to match the performance of animal-derived preparations across all clinical endpoints. The synthetic approach also eliminates batch-to-batch variability inherent in animal-sourced products and reduces the theoretical risk of transmitting animal-derived infections.

Surfactant Peptides and Lung Defense

SP-B and SP-C are not exclusively structural molecules. They participate in the lung's innate immune system in ways that are still being characterized.

Souza, Souza, and Pimentel showed in 2019 that the lung surfactant layer interacts with antimicrobial peptides like beta-defensin-3 at the air-water interface. The surfactant layer does not simply sit passively while defensins kill pathogens; instead, the lipid-protein film modulates how antimicrobial peptides reach and interact with microorganisms at the alveolar surface.^[3]

Cole and Waring reviewed the relationship between defensins and lung surfactant in 2002, documenting how alpha-defensins released by neutrophils during infection can disrupt surfactant function at high concentrations, contributing to the lung injury seen in acute respiratory distress syndrome (ARDS) in adults.^[4] The article on how antimicrobial peptides defend your lungs covers this immune dimension.

Tjabringa, Rabe, and Hiemstra characterized LL-37's role in the lung in 2005, finding that this cathelicidin functions both as a direct antimicrobial agent and as a modulator of inflammation within the surfactant-lined alveolar space.^[5] The interplay between structural surfactant peptides and antimicrobial peptides is a growing area of research, relevant to understanding why certain lung infections and inflammatory conditions impair gas exchange beyond what infection alone would explain. The LL-37 in respiratory immunity article covers this in depth.

Surfactant Dysfunction in Adult Disease

Surfactant problems are not limited to premature infants. Several adult conditions involve surfactant dysfunction.

Acute respiratory distress syndrome (ARDS): Inflammatory damage to alveolar cells and flooding of the alveolar space with protein-rich edema fluid inactivate surfactant. Plasma proteins compete with surfactant for space at the air-water interface, raising surface tension. Clinical trials of exogenous surfactant in adults with ARDS have shown mixed results, possibly because the doses and delivery methods optimized for tiny neonatal lungs are insufficient for the much larger adult lung.

COVID-19: SARS-CoV-2 infects type II alveolar cells (the surfactant-producing cells) through the ACE2 receptor, directly impairing surfactant production. Baindara and colleagues reviewed in 2023 how antimicrobial peptides at the alveolar surface could potentially prevent respiratory viral diseases by disrupting viral envelopes before they reach epithelial cells.^[6]

Interstitial lung disease: SP-C mutations cause a spectrum of chronic lung diseases through protein misfolding mechanisms rather than direct surfactant deficiency. The misfolded protein accumulates in the endoplasmic reticulum of type II alveolar cells, triggering a stress response that kills the cells responsible for surfactant production and alveolar repair. These conditions produce progressive fibrosis that can present anywhere from infancy to middle age and can be mistaken for idiopathic pulmonary fibrosis if genetic testing is not performed. Over 60 different SFTPC mutations have been identified, each producing a different clinical trajectory.

Guo and colleagues demonstrated in 2024 that the GLP-1 receptor agonist liraglutide could protect surfactant production during sepsis-induced acute lung injury in animal models, suggesting that peptide-based interventions beyond direct surfactant replacement may help preserve alveolar function during critical illness.^[7]

Beyond the Lungs: Surfactant-Like Peptides as Biomaterials

The self-assembling properties of surfactant peptides have attracted attention in materials science. Das and colleagues reported in 2025 that surfactant-like peptides form cross-beta amyloid fibrils that function as hydrogels, potential platforms for drug delivery and tissue engineering. These peptides spontaneously organize at interfaces in ways that mimic natural surfactant behavior but can be tuned for specific applications.^[8]

The surfactant replacement therapy article covers the clinical applications and ongoing improvements in neonatal care.

The Bottom Line

Surfactant proteins SP-B and SP-C are essential peptides that prevent lung collapse by reducing alveolar surface tension during every breath cycle. SP-B deficiency is fatal without lung transplantation. Surfactant replacement therapy, introduced in 1990, reduced premature infant mortality by approximately 40%. Synthetic peptide surfactants like lucinactant (KL4 peptide) and CHF5633 (SP-B + SP-C analogs) represent the next generation. Beyond their structural role, surfactant peptides interact with the lung's antimicrobial defense system and are impaired in adult diseases including ARDS and COVID-19.

Frequently Asked Questions

What are surfactant proteins SP-B and SP-C?

SP-B and SP-C are small hydrophobic peptides produced by type II alveolar cells in the lungs. SP-B (8.7 kDa) organizes phospholipids into a surface-active film at the air-water interface. SP-C (3.7 kDa) is the most hydrophobic protein in the human body and stabilizes the surfactant film during breathing compression cycles. Together, they reduce surface tension from 70 mN/m to near zero, preventing alveolar collapse (Braide-Moncoeur et al., Current Opinion in Chemical Biology, 2016).

What happens if surfactant protein B is missing?

Hereditary SP-B deficiency, caused by mutations in the SFTPB gene, produces severe respiratory failure in full-term newborns within hours of birth. The condition does not respond to exogenous surfactant therapy and is uniformly fatal without lung transplantation. The most common mutation (121ins2) accounts for two-thirds of cases. Estimated incidence is approximately 1 in 1 million live births.

How does surfactant replacement therapy save premature babies?

Premature infants born before 32 weeks lack sufficient surfactant because type II alveolar cells mature late in fetal development. Surfactant replacement therapy delivers surfactant directly into the trachea, restoring the surface-tension-lowering film that prevents alveolar collapse. Clinical trials demonstrated approximately 40% reduction in mortality from respiratory distress syndrome. Both animal-derived and synthetic peptide-based surfactants are available.

What is lucinactant and how does it work?

Lucinactant (Surfaxin), FDA-approved in 2012, is a synthetic surfactant containing sinapultide (KL4), a 21-amino acid peptide of repeating leucine-lysine units designed to mimic SP-B. The KL4 peptide reproduces the amphipathic helix that allows SP-B to organize phospholipids at the alveolar surface. Clinical trials showed non-inferiority to animal-derived surfactants for preventing RDS in premature infants (Braide-Moncoeur et al., 2016).

Can surfactant therapy help adults with ARDS?

Clinical trials of surfactant replacement in adults with acute respiratory distress syndrome have produced mixed results. The challenge is that adult lungs are much larger than neonatal lungs, inflammatory damage continuously inactivates administered surfactant, and plasma proteins flooding the alveoli compete with surfactant at the air-water interface. Optimizing dose, delivery method, and timing for adult applications remains an active research area.

Do surfactant proteins have immune functions?

Surfactant proteins participate in lung innate immunity beyond their structural role. SP-A and SP-D directly bind and neutralize pathogens. SP-B and SP-C modulate how antimicrobial peptides like beta-defensin-3 and LL-37 interact with microorganisms at the alveolar surface. During severe infection, neutrophil-released defensins can disrupt surfactant function, contributing to the gas exchange failure seen in ARDS (Cole and Waring, American Journal of Respiratory Medicine, 2002).